Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)
Mastrorosa et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.101895
https://c19early.org/mastrorosa.html